Srinagar: Hundreds of patients suffering from respiratory illnesses are facing hardship due to the absence of advanced lung ...
Allogeneic hematopoietic SCT (HCT) offers potentially curative therapy for patients with hematologic malignancies, but also carries significant risks. Assessing potential risk versus benefit is a ...
The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to identify ...
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
The European Respiratory Society (ERS) and American Thoracic Society (ATS) just updated their standards for interpreting lung function testing. The last joint society update from these organizations ...
A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...
Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC. Baseline DLCO 1.04 (0.99-1.1);p=0.1 1.04 ...
Long-term survival and competing causes of death in men with stage I seminoma. Background: Lung function testing (LFT) during chemotherapy with bleomycin is controversial. We describe the impact of ...
CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results